Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Prostatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 56Capecitabine 49Fluorouracil 37Cisplatin 37S 1 (combination) 23Paclitaxel 18Docetaxel 18Leucovorin 16pembrolizumab 13Irinotecan 12apatinib 11titanium silicide 9XELOX 9Trastuzumab 9Nivolumab 9Hyperthermic Intraperitoneal Chemotherapy 8Epirubicin 8Drug Therapy 8Tegafur 7Radiotherapy 6Neoadjuvant Therapy 6gimeracil 5Surgical Procedures, Operative 5Gastrectomy 5Chemotherapy, Adjuvant 5tislelizumab 4S-1 plus cisplatin 4Ramucirumab 4zolbetuximab 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Stomach Neoplasms × rofecoxib × Clear all
NCT00165048 2005-12-09

Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
206 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00164892 2005-11-17

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
214 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡